UA116007C2 - Композиції неорганічних наночастинок у комбінації з іонізуючим випромінюванням для лікування раку - Google Patents

Композиції неорганічних наночастинок у комбінації з іонізуючим випромінюванням для лікування раку

Info

Publication number
UA116007C2
UA116007C2 UAA201508289A UAA201508289A UA116007C2 UA 116007 C2 UA116007 C2 UA 116007C2 UA A201508289 A UAA201508289 A UA A201508289A UA A201508289 A UAA201508289 A UA A201508289A UA 116007 C2 UA116007 C2 UA 116007C2
Authority
UA
Ukraine
Prior art keywords
inorganic nanoparticles
ionizing radiations
combination
treating cancer
nanoparticles
Prior art date
Application number
UAA201508289A
Other languages
English (en)
Inventor
Ельза Боргі
Лоран Леві
Аньєс Поттьє
Original Assignee
Нанобіотікс
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Нанобіотікс filed Critical Нанобіотікс
Publication of UA116007C2 publication Critical patent/UA116007C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
    • A61N2005/1087—Ions; Protons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
    • A61N2005/1089—Electrons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device

Abstract

Винахід стосується способу індукування у суб'єкта-людини, що страждає від раку, (і) руйнування більш ніж 30 % ракових клітин в об'ємі пухлини або (іі) щонайменше більш ніж 20 % зниження розміру пухлини, який включає стадію введення вказаному суб'єкту композиції, що містить неорганічні наночастинки, що мають об'єм (Vin), що мають електронну густину, яка щонайменше в 5 разів перевищує електронну густину відповідного об'єму 1 (Vw1) води, так що вказана композиція займає між 2 і 50 % об'єму пухлини (Vt), і стадію піддавання вказаної пухлини вказаного суб'єкта дії іонізуючого випромінювання.
UAA201508289A 2013-01-25 2014-01-24 Композиції неорганічних наночастинок у комбінації з іонізуючим випромінюванням для лікування раку UA116007C2 (uk)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361756533P 2013-01-25 2013-01-25
EP13305087 2013-01-25
PCT/EP2014/051367 WO2014114732A1 (en) 2013-01-25 2014-01-24 Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer

Publications (1)

Publication Number Publication Date
UA116007C2 true UA116007C2 (uk) 2018-01-25

Family

ID=47710064

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201508289A UA116007C2 (uk) 2013-01-25 2014-01-24 Композиції неорганічних наночастинок у комбінації з іонізуючим випромінюванням для лікування раку

Country Status (23)

Country Link
US (4) US10098952B2 (uk)
EP (1) EP2948179B1 (uk)
JP (2) JP6619231B2 (uk)
KR (2) KR102385193B1 (uk)
CN (1) CN105120897B (uk)
AR (1) AR094577A1 (uk)
AU (1) AU2014209899B2 (uk)
BR (1) BR112015017490A2 (uk)
CA (2) CA3179586A1 (uk)
CY (1) CY1121838T1 (uk)
EA (1) EA034242B1 (uk)
HK (1) HK1216609A1 (uk)
IL (1) IL239767B (uk)
MA (1) MA38318A1 (uk)
MX (1) MX369664B (uk)
PL (1) PL2948179T3 (uk)
RS (1) RS59042B1 (uk)
SG (1) SG11201505277VA (uk)
SI (1) SI2948179T1 (uk)
TW (1) TW201442726A (uk)
UA (1) UA116007C2 (uk)
WO (1) WO2014114732A1 (uk)
ZA (1) ZA201505510B (uk)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10945965B2 (en) 2011-12-16 2021-03-16 Nanobiotix Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof
PL2948179T3 (pl) 2013-01-25 2019-10-31 Nanobiotix Kompozycje zawierające nanocząstki tlenku hafnu(iv) lub tlenku renu(iv) w połączeniu z promieniowaniem jonizującym do leczenia nowotworu
EP2886128A1 (en) * 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
CN107708668A (zh) 2015-05-28 2018-02-16 纳米生物技术公司 用作治疗性疫苗的纳米粒子
US11247054B2 (en) * 2016-12-21 2022-02-15 Nanobiotix S.A. Nanoparticles for use for enhancing brain performances or for treating stress
BR112019012984A2 (pt) * 2016-12-21 2019-12-03 Nanobiotix nanopartículas para uso para tratar um transtorno neuronal
EP3424533A1 (en) * 2017-07-05 2019-01-09 Nh Theraguix Methods for treating tumors
US11173325B2 (en) * 2017-07-21 2021-11-16 Varian Medical Systems, Inc. Methods of use of ultra-high dose rate radiation and therapeutic agent
US20220249389A1 (en) * 2019-07-12 2022-08-11 Oregon Health & Science University Immunotherapeutic constructs and methods of their use
KR20220035161A (ko) 2019-07-12 2022-03-21 오레곤 헬스 앤드 사이언스 유니버시티 유사분열 키나제 억제제 및 면역 체크포인트 억제제의 공동-전달을 위한 치료 구축물
WO2021011496A1 (en) * 2019-07-12 2021-01-21 Oregon Health & Science University Immunotherapeutic constructs and methods of their use
EP4141110A1 (en) 2020-04-24 2023-03-01 Obshchestvo S Ogranichennoy Otvetstvennost'yu "Ingenik" Method for producing particles of bacteriophages of the genus levivirus

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006244A2 (en) * 1998-07-30 2000-02-10 Hainfeld James F Loading metal particles into cell membrane vesicles and metal particle use for imaging and therapy
AU2002218087A1 (en) * 2000-11-20 2002-05-27 Oncolytics Biotech Inc. Method for optimally delivering virus to a solid tumor mass
US6756063B2 (en) * 2001-03-29 2004-06-29 Zoltan Laboratories, Llc Methods and compositions for the treatment of human and animal cancers
FR2884149B1 (fr) * 2005-04-12 2007-06-08 Henri Mehier Tube implantable destine a l'injection notamment de fluide caloporteur dans tout ou partie d'un tissu humain ou animal
EP2130553A1 (en) * 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
US8395131B2 (en) * 2009-06-20 2013-03-12 Xiaodong Wu Method for three dimensional (3D) lattice radiotherapy
EP2275137A1 (en) * 2009-07-10 2011-01-19 Nanobiotix Metallic nanoparticles, preparation and uses thereof
WO2011127061A1 (en) 2010-04-05 2011-10-13 Nanospectra Biosciences, Inc. Enhancement of radiation therapy by targeted high-z nanoparticles
US10945965B2 (en) 2011-12-16 2021-03-16 Nanobiotix Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof
PL2948179T3 (pl) 2013-01-25 2019-10-31 Nanobiotix Kompozycje zawierające nanocząstki tlenku hafnu(iv) lub tlenku renu(iv) w połączeniu z promieniowaniem jonizującym do leczenia nowotworu

Also Published As

Publication number Publication date
WO2014114732A1 (en) 2014-07-31
CN105120897A (zh) 2015-12-02
PL2948179T3 (pl) 2019-10-31
EA201591378A1 (ru) 2016-04-29
EP2948179A1 (en) 2015-12-02
IL239767A0 (en) 2015-08-31
SI2948179T1 (sl) 2019-09-30
AU2014209899B2 (en) 2018-05-24
US10098952B2 (en) 2018-10-16
MA38318A1 (fr) 2017-02-28
EA034242B1 (ru) 2020-01-21
RS59042B1 (sr) 2019-08-30
BR112015017490A2 (pt) 2017-07-11
TW201442726A (zh) 2014-11-16
IL239767B (en) 2018-10-31
AR094577A1 (es) 2015-08-12
KR102225239B1 (ko) 2021-03-09
CY1121838T1 (el) 2020-07-31
CA3179586A1 (en) 2014-07-31
CA2897362C (en) 2023-02-14
CN105120897B (zh) 2017-12-05
MX369664B (es) 2019-11-14
CA2897362A1 (en) 2014-07-31
KR102385193B1 (ko) 2022-04-12
JP2016505061A (ja) 2016-02-18
MX2015009409A (es) 2016-03-16
KR20150108923A (ko) 2015-09-30
EP2948179B1 (en) 2019-06-19
ZA201505510B (en) 2016-12-21
US11020480B2 (en) 2021-06-01
US11819548B2 (en) 2023-11-21
US20210283256A1 (en) 2021-09-16
HK1216609A1 (zh) 2016-11-25
US20190008962A1 (en) 2019-01-10
AU2014209899A1 (en) 2015-07-23
JP2018168162A (ja) 2018-11-01
JP6619231B2 (ja) 2019-12-11
SG11201505277VA (en) 2015-08-28
KR20210027536A (ko) 2021-03-10
US20240100163A1 (en) 2024-03-28
US20150374818A1 (en) 2015-12-31

Similar Documents

Publication Publication Date Title
MX369664B (es) Composiciones de nanoparticulas inorganicas en combinacion con radiaciones ionizantes para tratar el cancer.
PH12018502429A1 (en) Antibody molecules for cancer treatment
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
WO2016025635A3 (en) Combination therapy for treating cancer
MX2016007351A (es) Terapia de combinacion para tratar cancer.
MX2019001920A (es) Arn la terapia contra el cancer.
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
MX2019010601A (es) Terapia de combinacion para tratar cancer.
NZ749218A (en) Androgen receptor modulator and uses thereof
SG10201902664RA (en) Combination therapy for treating cancer
WO2015009726A3 (en) Medical uses of cd38 agonists
WO2016043874A3 (en) Combination therapy for treating cancer
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
MX2015012922A (es) Tratamiento del cancer usando anticuerpos que se unen a grp78 en la superficie celular.
EA201591925A1 (ru) Терапевтические композиции и их применение
MX2020001727A (es) Terapia de combinacion.
MX2019013862A (es) Terapia de combinacion.
MX2018000052A (es) Composiciones y métodos para la terapia combinada con virus del dengue y celulas dendríticas.
MX2023007706A (es) Nanoparticulas para su uso como vacuna terapeutica.
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.
NZ709685A (en) Inorganic nanoparticles compositions in combination with ionizing radiations for treating cancer
MX2021001081A (es) Terapia de combinacion para el tratamiento del cancer.
MX2019014842A (es) Uso de una combinación de ivosidenib y radiación para tratar gliomas.
MX2017013668A (es) Terapia de combinacion de agente anti-fuctactico y agente anti-cancer y composiciones para el tratamiento de cancer.
Doornaert et al. Non-coplanar volumetric modulated arc therapy for irradiation of paranasal sinus tumors: In response to Al-Mamgani et al., Highly-conformal intensity-modulated radiotherapy reduced toxicity without jeopardizing outcome in patients with paranasal sinus cancer treated by surgery and radiotherapy or (chemo) radiation. Oral Oncol 2012; 48 (9): 905-11